Validating aurora b as an anticancer drug target

Accumulating evidence support the involvement of Aurora proteins in a wide range of tumors including breast [9,10], colon [11–13], pancreas [14], ovary [15], stomach [16], thyroid [17], head and neck [18].This has increased the possibility of developing new anti-cancer drugs that could target Aurora kinases.2D property profiles were generated to check whether a compound is “drug-like” and whether it is synthetically accessible or orally bio-available.

Typically, kinase paralogs influence by regulating the cell cycle and their malfunction may lead to cancer phenotype.

VS is usually described as a cascade of filter approaches to narrow down a set of compounds to be tested for biological activity against the intended drug target.

Starting with a fast evaluation of druglikeness of compounds, VS is often followed by ligand-based and/or structure-based approaches, only if the target structure is available [30].

Mitosis is a vital process required for tissue regeneration, genomic development and to maintain the functional integrity of a cell [3].

So far, three types of Aurora kinases are reported in mammals, designated as A, B and C, which share a high sequence homology at amino acid level.

Leave a Reply